4.5 Article

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

期刊

VACCINE
卷 26, 期 51, 页码 6678-6684

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.09.006

关键词

SARS; Modified Vaccinia virus Ankara; Adjuvant; Mucosal immunization; Prime boost

资金

  1. Bayerische Forschungsstiftung [PIZ 26/03]
  2. Friedrich-Schiedel-Stiftung of the Technical University Munich [5110095 TG 04]

向作者/读者索取更多资源

Severe acute respiratory syndrome (SARS) is a Serious infectious disease Caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based oil the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in pruning with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route. (C) 2008 Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据